Autologous tumour cell vaccine - Champions Oncology/Gradalis/Mary Crowley

Drug Profile

Autologous tumour cell vaccine - Champions Oncology/Gradalis/Mary Crowley

Alternative Names: Bi-shRNAfurin; bi-shRNAfurin and GMCSF Autologous Tumor Cell Immunotherapy; FANG vaccine; FANG™; TAG vaccine; TGFbeta2 antisense + rhGMCSF vaccine; Vigil EATC; Vigil™

Latest Information Update: 15 May 2017

Price : $50

At a glance

  • Originator Gradalis
  • Developer Gradalis; Mary Crowley Cancer Research Center
  • Class Cancer vaccines; Tumour cell vaccines
  • Mechanism of Action Furin expression inhibitors; Granulocyte-macrophage colony-stimulating factor expression stimulants; Immunostimulants; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Ovarian cancer
  • Phase II/III Breast cancer
  • Phase II Ewing's sarcoma; Liver metastases; Malignant melanoma
  • Phase I Solid tumours

Most Recent Events

  • 04 May 2017 Gradalis withdraws a phase II trial prior to enrolment in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Intradermal) (NCT02639234)
  • 10 Mar 2017 Gradalis and Roche plan a phase III trial for Gynaecological cancers (Combination therapy) (NCT03073525)
  • 21 Dec 2016 Gradalis and Genentech agree to co-develop autologous tumour cell vaccine combined with atezolizumab in USA for Ovarian cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top